贝伐珠单抗联合鸦胆子油胶囊对晚期非小细胞肺癌的治疗效果及对患者免疫功能、生存质量的影响

Therapeutic effect of bevacizumab combined with Brucea javanica oil capsule on advanced non-small cell lung cancer and its influence on patients'immune function and quality of life

目的探讨贝伐珠单抗联合鸦胆子油胶囊对晚期非小细胞肺癌(NSCLC)的治疗效果及其对患者免疫功能、生存质量的影响。方法回顾性选取2017年9月至2022年9月淮安市第二人民医院收治的晚期NSCLC患者60例,根据治疗方法不同分为A组(贝伐珠单抗+放化疗)、B组(鸦胆子油胶囊+放化疗)、C组(贝伐珠单抗+鸦胆子油胶囊+放化疗),每组20例。评价各组的治疗效果、免疫功能及生存质量,并进行统计比较。结果3组疾病控制率比较,差异无统计学意义(P>0.05),C组客观有效率为70.00%,明显高于A组、B组(30.0%、35.0%),差异有统计学意义(P<0.05)。治疗后,C组CD3^(+)为(63.49±9.03)%,显著高于A组、B组[(56.33±7.90)%、(58.78±8.22)%],CD3^(+)CD8^(+)为(21.93±1.00)%,低于A组、B组[(23.94±1.65)%、(22.89±1.54)%],差异有统计学意义(P<0.05)。治疗后,C组FACT-L量表总得分为(121.64±18.03)分,显著高于A组、B组[(95.72±16.61)、(108.39±15.44)分],差异有统计学意义(P<0.05)。C组中位无进展生存时间(PFS)及总生存时间(OS)均显著长于A组和B组,差异均有统计学意义(P<0.05)。B组和C组胃肠道反应发生率明显低于A组,差异有统计学意义(P<0.05)。结论贝伐珠单抗联合鸦胆子油胶囊可明显提高晚期NSCLC患者在放化疗过程中的治疗效果,提高机体免疫功能,延长生存期,减少毒副反应,改善患者生存质量。

Objective To explore the therapeutic effect of bevacizumab combined with Brucea javanica oil capsule on advanced non-small cell lung cancer(NSCLC)and its impact on immune function and quality of life of patients.Methods Sixyty patients with advanced NSCLC admitted to Huai'an Second People's Hospital from September 2017 to September 2022 were divided into group A(bevacizumab+radiochemotherapy),group B(Brucea javanica oil capsule+radiochemotherapy),and group C(bevacizumab+Brucea javanica oil capsule+radiochemotherapy)according to different treatment methods,with 20 patients in each group.The therapeutic effect,immune function and quality of life of each group were evaluated and compared.Results There was no statistically significant difference in disease control rate among the three groups(P>0.05),while the objective effective rate of group C was 70.00%,which was significantly higher than that of group A(30.0%)and group B(35.0%),and the differences were statistically significant(P<0.05).After treatment,CD3^(+)of group C was(63.49±9.03)%,which was significantly higher than that of group A and group B[(56.33±7.90)%,(58.78±8.22)%],and CD3^(+)CD8^(+)was(21.93±1.00)%,which was lower than that of groups A and B[(23.94±1.65)%,(22.89±1.54)%],and the differences were statistically significant(P<0.05).After treatment,the total score of the FACT-L scale in group C was(121.64±18.03)points,which was significantly higher than that in group A and group B[(95.72±16.61)and(108.39±15.44)points],and the differences were statistically significant(P<0.05).The median progression free survival(PFS)and overall survival(OS)in group C were significantly longer than those in group A and group B,and the differences were statistically significant(P<0.05).The incidence of gastrointestinal reaction in group B and C was significantly lower than that in group A,and the differences were statistically significant(P<0.05).Conclusion Bevacizumab combined with Brucea javanica oil capsule can significantly improve the therapeutic effect of radiochemotherapy in patients with advanced NSCLC,improve the immune function of the body,prolong the survival period,reduce toxic side effects,and improve the quality of life of patients.